Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 5/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | ITGB1 | P05556 | 6/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.46 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.44 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.44 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6709419 | 0.91 | ITGA4 (0.51) | ITGA4L3MBTL1ITGB1HCRTR1HCRTR2 | |
| SCHEMBL6712256 | 0.90 | ITGA4 (0.52) | ITGA4L3MBTL1ITGB1HCRTR1HCRTR2 | |
| SCHEMBL7383363 | 0.88 | ITGA4 (0.59) | ITGA4L3MBTL1ITGB1HCRTR1HCRTR2 | |
| SCHEMBL6712483 | 0.88 | ITGA4 (0.57) | ITGA4L3MBTL1ITGB1MAPTGAA | |
| SCHEMBL7071151 | 0.86 | ITGA4 (0.58) | ITGA4L3MBTL1ITGB1GAAHPGD | |
| SCHEMBL7314087 | 0.85 | ITGA4 (0.57) | ITGA4L3MBTL1ITGB1GAAHPGD | |
| SCHEMBL5690673 | 0.85 | ITGA4 (0.65) | ITGA4L3MBTL1ITGB1MAPTGAA | |
| SCHEMBL3855640 | 0.83 | ITGA4 (0.52) | ITGA4ITGB1HCRTR1HCRTR2MAPT | |
| SCHEMBL3857921 | 0.83 | ITGA4 (0.54) | ITGA4ITGB1MAPTGAAHPGD | |
| SCHEMBL7377415 | 0.83 | ITGA4 (0.57) | ITGA4L3MBTL1ITGB1HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040006093-A1 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2004-01-08 | — | — | US | claimed |
| US-6583139-B1 | Treatment of inflammatory diseases; inflammatory brain diseases such as multiple sclerosis; N-(Toluene-4-sulfonyl)-L-prolyl-4-(alpha -methylbenzyloxy)-L-phenylalanine; Very Late Antigen 4 | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2003-06-24 | — | — | US | claimed |
| US-20040006093-A1 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2004-01-08 | — | — | US | disclosed |
| US-6583139-B1 | Treatment of inflammatory diseases; inflammatory brain diseases such as multiple sclerosis; N-(Toluene-4-sulfonyl)-L-prolyl-4-(alpha -methylbenzyloxy)-L-phenylalanine; Very Late Antigen 4 | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2003-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006093-A1 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, CD4 | ITGA4 9/4885L3MBTL1 448/4885ITGB1 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.